TCGA-AC-A3EH-01A-22R-A22K-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 7
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.370
- APICAL_JUNCTION+0.320
- COAGULATION+0.240
- HEDGEHOG_SIGNALING+0.240
- OXIDATIVE_PHOSPHORYLATION+0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.170
- MYOGENESIS+0.160
- CHOLESTEROL_HOMEOSTASIS+0.150
- XENOBIOTIC_METABOLISM+0.150
- GLYCOLYSIS+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.380
- E2F_TARGETS-0.380
- G2M_CHECKPOINT-0.330
- MYC_TARGETS_V1-0.290
- INFLAMMATORY_RESPONSE-0.240
- TNFA_SIGNALING_VIA_NFKB-0.220
- KRAS_SIGNALING_UP-0.210
- COMPLEMENT-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518125 | — | F | 0.854 |
| 2 | SRR8613710 | — | F | 0.796 |
| 3 | SRR8613741 | — | F | 0.789 |
| 4 | ae30907a-a08a-44f3-b656-b0ba9729c8e7 | — | — | 0.785 |
| 5 | SRR8518172 | — | E | 0.775 |
| 6 | 290b89f5-2a44-424b-b77d-a190dcb93e07 | — | — | 0.772 |
| 7 | TCGA-73-4675-01A-01R-1206-07 | — | cohortA2 | 0.757 |
| 8 | MDT-AP-0823 | Med | Medulloblastoma | 0.756 |
| 9 | MNG1264 | — | — | 0.748 |
| 10 | 59364db9-7bf7-4a15-9798-8e3886078012 | — | — | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.050 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |